Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of ...

The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...

New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of ind ...

The DMD franchise significantly contributed with $547 million in revenue. The company ended the year with over $1.1 billion in cash reserves, further strengthened by a $1 billion payment from Novartis ...

The DMD franchise significantly contributed with $547 million in revenue. The company ended the year with over $1.1 billion in cash reserves, further strengthened by a $1 billion payment from ...

EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is ...

Like other protein-coding genes, the DMD gene is composed of sections called exons, many of which come together to form the gene, not unlike how different words are put together to make a sentence.

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA lifted a more than two-year-long hold. Dubbed ENTR-601-44, the endosomal ...

Presentation Details: Title: ARCUS-Mediated Excision of Exons 45-55 Leads to Functional Del45-55 Dystrophin and Restoration of Skeletal Muscle-Function for the Treatment of DMD Date and Time ...

Detailed price information for Entrada Therapeutics Inc (TRDA-Q) from The Globe and Mail including charting and trades.

Title: ARCUS-Mediated Excision of Exons 45-55 Leads to Functional Del45-55 Dystrophin and Restoration of Skeletal Muscle-Function for the Treatment of DMD Date and Time: Wednesday, March 19, 2025, ...